Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment
about
Alzheimer's disease as homeostatic responses to age-related myelin breakdownLipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's diseaseApoE promotes the proteolytic degradation of AbetaAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner.Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.The vascular contribution to Alzheimer's disease.Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 miceNuclear receptors in neurodegenerative diseases.Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.ABC Transporters and the Alzheimer's Disease Enigma.Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 MiceLiver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient miceLevels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samplesLiver X receptor-β improves autism symptoms via downregulation of β-amyloid expression in cortical neuronsThe role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegenerationMemory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomersGenome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration.Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).LXR agonists: new potential therapeutic drug for neurodegenerative diseases.ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo.The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis.Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer's mice.Liver X receptors regulate cerebrospinal fluid production.Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats.Treatment with LXR agonists after focal cerebral ischemia prevents brain damage.Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury.Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion.Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer's Disease
P2860
Q22251261-C05D1768-9231-4808-BC79-0418D3837C96Q24650450-9E043E14-A270-47CA-A358-B4E4FEA4EFB4Q24651102-996121C9-5BC5-40BC-8811-6FDA1608E56FQ28085213-D87B5945-CBE0-4627-8598-BE84669D1AC9Q30497102-5E97ECA0-CB99-4FF8-B9EB-3CE7AD2560FCQ30572801-A36367F1-D6B8-4365-B63F-8488F3CD0E5FQ33906674-3AB0604C-2D4A-4A88-8130-7A2CD0D32510Q34178526-8248A268-85AA-48D7-8976-FA58F636BCE2Q34299304-92BFC6CE-E011-41AB-9E39-1EB50F6A9FC0Q34580020-13A2A2D7-EFD3-4E6F-98F0-7FC2FE2CBA5FQ35694025-4AD86761-FCC6-46F5-B016-FBE8F6C13635Q36005085-93EF32DF-201C-41E4-BC91-0919959CAE65Q36065117-36AD1FF9-5565-4E70-AB56-9D98FB8024E1Q36291665-97B62553-A3F3-4810-BBDD-D2B578BD4DD1Q36635968-5B7B6594-BD05-4C0B-80A2-8423E89D6835Q36879758-784AAD6A-FF0E-4091-A9E2-5A91FF789EEBQ37017266-34D5B25D-BCF2-493B-A754-A08D6A857EF4Q37225388-E3E82032-1797-4864-B818-A98762984BCEQ37610911-9B381A67-85F1-480E-907F-2C0C9A68020FQ37714905-1FB47133-AAD2-415A-BB82-1E8775098816Q38102608-BA33FAFC-6E54-4ED3-9FD3-F748EE3E44EBQ38293052-E60219D2-5DE0-44DD-A73E-E8EE2D9ADAA3Q38818532-6D997DCE-6824-4FB8-98B4-431BC415D42BQ39164346-4EDA3644-2A62-436A-8CF0-CC774F1A10F6Q39495324-BA8B6CBA-8AF0-43ED-B615-523900DA257DQ39605286-F9A244E6-705C-4288-B668-62C69FB7041EQ40589497-99453B30-CF45-4E46-B71A-612982F66DB3Q41702367-1732E635-7B87-40F3-9099-AD702845B588Q42697923-A13DED58-E33C-4A2B-92D4-081E0976628AQ43211435-626BFBF7-4BB8-4789-A27E-F1721BA177DEQ48221935-09C08F7D-F921-4FC2-94F4-9028B2F1B7D1Q52631118-A245C3B2-A0FA-4F65-84F6-CC9A928490D8Q57816569-CE987597-2614-4242-9D16-4A2488DFC32E
P2860
Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@ast
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@en
type
label
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@ast
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@en
prefLabel
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@ast
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@en
P2093
P2860
P356
P1476
Expression profiling in APP23 ...... ponse to LXR agonist treatment
@en
P2093
Angie Bookout
David Mangelsdorf
Iliya Lefterov
Radosveta Koldamova
P2860
P2888
P356
10.1186/1750-1326-2-20
P577
2007-10-22T00:00:00Z
P5875
P6179
1010476301